EML4 and non-small cell lung carcinoma: In 2016, the world’s first cancer diagnostic product based on exosome miRNAs body fluid biopsy, ExoDx Lung (ALK), was launched, which could detect EML4-ALK mutations in patients with non-small cell lung cancer in real time [113].